New drug cocktail shows promise against tough esophageal cancer
NCT ID NCT07374003
First seen Jan 30, 2026 · Last updated Jun 04, 2026 · Updated 16 times
Summary
This study tests whether adding two immunotherapy drugs (ipromlimab and tuvonralimab) to standard chemotherapy before surgery can help shrink tumors in people with locally advanced esophageal cancer. About 62 participants will receive the combination treatment. The main goal is to see how many patients have no cancer cells left in their surgical tissue sample.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED, RESECTABLE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sub-i
Guangdong, GUANGZHOU, 510000, China
Conditions
Explore the condition pages connected to this study.